Knocking down gene expression with dendritic vectors

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 73-86

  Ravina M ^a   Paolicelli, P ^b   Seijo, B ^a   Sanchez, A ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antisense delivery; Antisense therapy; Dendrimers; Dendriplexes; Gene silencing; Gene therapy; Knocking down; siRNA delivery

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARBOSILANE; DENDRIMER; POLYAMIDOAMINE; POLYLYSINE; POLYPROPYLENIMINE; RIBOZYME; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; CHEMICAL STRUCTURE; DENDRITIC CELL; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HUMAN; NONHUMAN; REVIEW; RNA INTERFERENCE;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); DENDRIMERS; DNA, CATALYTIC; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE THERAPY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA, CATALYTIC; RNA, SMALL INTERFERING;

EID: 77951122502     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791112569     Document Type: Review

References (86)

1. Zamecnik, P. C.; Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Nat. Acad. Sci. USA, 1978, 75, 280-284.
2. Akhtar, S.; Hughes, M. D.; Khan, A.; Bibby, M.; Hussain, M.; Nawaz, Q.; Double, J.; Sayyed, P. The delivery of antisense therapeutics. Adv. Drug Del. Rev.s, 2000, 44, 3-21.
3. Leaman, D. W. Recent progress in oligonucleotide therapeutics: Antisense to aptamers. Expert Opin. Drug Discov., 2008, 3, 997-1009.
4. Rayburn, E. R.; Zhang, R. Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible? Drug Discov. Today, 2008, 13, 513-521.
5. Bhindi, R.; Fahmy, R. G.; Lowe, H. C.; Chesterman, C. N.; Dass, C. R.; Cairns, M. J.; Saravolac, E. G.; Sun, L. Q.; Khachigian, L. M. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am. J. Pathol., 2007, 171, 1079-1088.
6. Perry, C. M.; Balfour, J. A. B. Fomivirsen. Drugs, 1999, 57, 375-381.
7. Baker, B. F.; Lot S. S.; Condon, T. P.; Cheng-Flournoy, S.; Lesnik, E. A.; Sasmor, H. M.; Bennett, C. F. 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J. Biol. Chem, 1997, 272, 11994-12000.
8. Walder, R. Y.; Walder, J. A. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA, 1988, 85, 5011-5015.
9. Dias, N.; Dheur, S.; Nielsen, P. E.; Gryaznov, S.; Van Aerschot, A.; Herdewijn, P.; Helene, C.; Saison-Behmoaras, T. E. Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J. Mol. Biol., 1999, 294, 403-416.
10. Kurreck, J. Antisense technologies: Improvement through novel chemical modifications. Eur. J. Biochem., 2003, 270, 1628-1644.
11. Herdewijn, P. Heterocyclic modifications of oligonucleotides and antisense technology. Antisense and Nucleic Acid Drug Dev., 2000, 10, 297-310.
12. Elbashir S. M.; Harborth J.; Lendeckel W.; Yalcin A.; Weber K.; Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411, 494-498.
13. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver S. E.; Mello C. C. Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nat., 1998, 391, 806-811.
14. Bernstein E.; Caudy A. A.; Hammond S. M.; Hannon G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nat., 2001, 409, 363-366.
15. Nykänen, A.; Haley, B.; Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell, 2001, 107, 309-321.
16. Hammond, S. M.; Bernstein E.; Beach D.; Hannon G. J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature, 2000, 404, 293-296.
17. Dowler, T.; Bergeron, D.; Tedeschi, A. L.; Paquet, L.; Ferrari, N.; Damha, M. J. Improvements in siRNA properties mediated by 2′-deoxy- 2′-fluoro-β-D-arabinonucleic acid (FANA). Nucleic Acids Res., 2006, 34, 1669-1675.
18. Morrissey, D. V.; Lockridge, J. A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; Vaish, N.; Zinnen, S.; Vargeese, C.; Bowman, K.; Shaffer, C. S.; Jeffs, L. B.; Judge, A.; MacLachlan, I.; Polisky, B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotech., 2005, 23, 1002-1007.
19. Guerrier-Takada, C.; Gardiner, K.; Marsh, T. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell, 1983, 35, 849-857.
20. Isaka, Y.; Imai, E.; Takahara, S.; Rakugi, H. Oligonucleotidic therapeutics. Exp. Opin. Drug Discov., 2008, 3, 991-996.
21. Santoro, S. W.; Joyce, G. F. A general purpose RNA-cleaving DNA enzyme. Proc. Nat. Acad. Sci. USA,, 1997, 94, 4262-4266.
22. Tan, M. L.; Choong, P. F. M.; Dass, C. R. DNAzyme delivery systems: Getting past first base. Expert Opinion on Drug Delivery, 2009, 6, 127-138.
23. Aagaard, L.; Rossi, J. J. RNAi therapeutics: Principles, prospects and challenges. Adv. Drug Del. Rev., 2007, 59, 75-86.
24. Dykxhoorn, D. M.; Lieberman, J. Knocking down Disease with siRNAs. Cell, 2006, 126, 231-235.
25. Opalinska, J. B.; Gewirtz, A. M. Nucleic-acid therapeutics: Basic principles and recent applications. Nat. Rev. Drug Discov., 2002, 1, 503-514.
26. Boas U.; Heegaard P. M. H. Dendrimers in drug research. Chem. Soc. Rev., 2004, 33, 43-63.
27. Carlmark, A.; Hawker, C.; Hult, A.; Malkoch, M. New methodologies in the construction of dendritic materials. Chem. Soc. Rev., 2009, 38, 352-362.
28. Svenson, S.; Tomalia, D. A. Dendrimers in biomedical applications - Reflections on the field. Adv. Drug Del. Rev., 2005, 57, 2106-2129.
29. Dufes, C.; Uchegbu, I. F.; Schatzlein, A. G. Dendrimers in gene delivery. Adv. Drug Del. Rev., 2005, 57, 2177-2202.
30. Guillot-Nieckowski, M.; Eisler, S.; Diederich, F. Dendritic vectors for gene transfection. New J. Chem., 2007, 31, 1111-1127.
31. Tomalia, D. A.; Baker, H.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. New class of polymers: Starburst-dendritic macromolecules Polym. J., 1984, 17, 117-132.
32. Kang, H.; DeLong, R.; Fisher, M. H.; Juliano, R. L. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res., 2005, 22, 2099-2106.
33. Poxon, S. W.; Mitchell, P. M.; Liang, E.; Hughes, J. A. Dendrimer delivery of oligonucleotides. Drug Deliv., 1996, 3, 255-261.
34. Wu, J.; Zhou, J.; Qu, F.; Bao, P.; Zhang, Y.; Peng, L. Polycationic dendrimers interact with RNA molecules: Polyamine dendrimers inhibit the catalytic activity of Candida ribozymes. Chem. Commun., 2005, 313-315.
35. DeLong R.; Stephenson K.; Loftus T.; Fisher M.; Alahari S.; Nolting A.; Juliano R. L. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci., 1997, 86, 762-764.
36. Hong, S.; Bielinska, A. U.; Mecke, A.; Keszler, B.; Beals, J. L.; Shi, X.; Balogh, L.; Orr, B. G.; Baker, Jr. J. R.; Banaszak Holl, M. M. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: Hole formation and the relation to transport. Bioconj. Chem., 2004, 15, 774-782.
37. Mecke, A.; Majoros, I. J.; Patri, A. K.; Baker, J. R. Jr.; Holl, M. M.; Orr, B. G. Lipid bilayer disruption by polycationic polymers: the roles of size and chemical functional group. Langmuir, 2005, 21, 10348-10354.
38. Lee, H. Molecular dynamics simulations of PAMAM dendrimer-induced pore formation in DPPC bilayers with a coarse-grained model. J. Phys.Chem. B, 2006, 110, 18204-18211.
39. Manunta M.; Tan P. H.; Sagoo P.; Kashefi K.; George A. J. T. Gene delivery by dendrimers operates via a cholesterol dependent pathway. Nucleic Acids Res., 2004, 32, 2730-2739.
40. Manunta, M.; Nichols, B. J.; Hong, Tan, P.; Sagoo, P.; Harper, J.; George, A. J. T. Gene delivery by dendrimers operates via different pathways in different cells, but is enhanced by the presence of caveolin. J. Immunol. Methods, 2006, 314, 134-146.
41. Sonawane, N. D.; Szoka, Jr. F. C.; Verkman, A. S. Chloride Accumulation and Swelling in Endosomes Enhances DNA Transfer by Polyamine-DNA Polyplexes. J. Biol. Chem., 2003, 278, 44826-44831.
42. Bielinska, A.; Kukowska-Latallo, J. F.; Johnson,J.; Tomalia, D. A.; Baker, Jr., J. R. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res., 1996, 24, 2176-2182.
43. Yoo, H.; Sazani, P.; Juliano, R. L. PAMAM dendrimers as delivery agents for antisense oligonucleotides. Pharm. Res., 1999, 16, 1799-1804.
44. Geselowitz, D. A.; Neckers, L. M. Bovine serum albumin is a major oligonucleotide-binding protein found on the surface of cultured cells. Antisense Res. Dev., 1995, 5, 213-217.
45. Henry, S. P.; Novotny, W.; Leeds, J.; Auletta C.; Kornbrust D. J. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev., 1997, 7, 503-510.
46. Srinivasan, S. K.; Tewary, H. K.; Iversen, P. L. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev., 1995, 5, 131-139.
47. Tang, M. X.; Redemann, C. T.; Szoka, Jr., F. C. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconj. Chem., 1996, 7, 703-714.
48. Zhou, J.; Wu, J.; Hafdi, N.; Behr, J. P.; Erbacher, P.; Peng, L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem. Commun., 2006, 2362-2364.
49. Yoo, H.; Juliano, R. L. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res., 2000, 28, 4225-4231.
50. Dung, T. H.; Kim, J. S.; Juliano, R. L.; Yoo, H. Preparation and evaluation of cholesteryl PAMAM dendrimers as nano delivery agents for antisense oligonucleotides. Colloid. Surface. Physicochemical Eng. Aspect., 2008, 313-314, 273-277.
51. Nam, H. Y.; Hahn, H. J.; Nam, K.; Choi, W. H.; Jeong, Y.; Kim, D. E.; Park, J. S. Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. Int. J. Pharm., 2008, 363, 199-205.
52. Jevprasesphant, R.; Penny, J.; Jalal, R.; Attwood, D.; McKeown, N. B.; D'Emanuele, A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm., 2003, 252, 263-266.
53. Tsutsumi, T.; Hirayama, F.; Uekama, K.; Arima, H. Evaluation of polyamidoamine dendrimer/α-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). J. Control. Release, 2007, 119, 349-359.
54. Arima, H.; Kihara, F.; Hirayama, F.; Uekama, K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with α-, β-, and γ-cyclodextrins. Bioconj. Chem., 2001, 12, 476-484.
55. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev., 2005, 57, 2215-2237.
56. Malik, N.; Wiwattanapatapee, R.; Klopsch, R.; Lorenz, K.; Frey, H.; Weener, J. W.; Meijer, E. W.; Paulus, W.; Duncan, R. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control. Rel., 2000, 65, 133-148.
57. Roberts, J. C.; Bhalgat, M. K.; Zera, R. T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburstâ,¢ dendrimers. J. Biomed. Mater. Res., 1996, 30, 53-65.
58. Satija, J.; Gupta, U.; Jain, N. K. Pharmaceutical and biomedical potential of surface engineered dendrimers. Crit. Rev. Ther. Drug Carrier Syst., 2007, 24, 257-306.
59. Yellepeddi, V. K.; Kumar, A.; Palakurthi, S. Surface modified poly(amido) amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opinion Drug Deliv., 2009, 6, 835-850.
60. Patil, M. L.; Zhang, M.; Betigeri, S.; Taratula, O.; He, H.; Minko, T. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug. Chem., 2008, 19, 1396-1403.
61. Kim, Y.; Klutz, A. M.; Jacobson, K. A. Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity. Bioconjug Chem, 2008, 19, 1660-1672.
62. Wang W.; Xiong W.; Wan J.; Sun X.; Xu H.; Yang X. The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology, 2009, 20, 105103.
63. Qi R.; Gao, Y.; Tang, Y.; He, R. R.; Liu, T. L.; He,Y.; Sun, S.; Li, B. Y.; Li, Y. B.; Liu, G. PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression. A.A.P.S. J., 2009, 11, 395-405.
64. Hollins, A. J.; Benboubetra, M.; Omidi, Y.; Zinselmeyer, B. H.; Schatzlein, A. G.; Uchegbu, I. F.; Akhtar, S. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm. Res., 2004, 21, 458-466.
65. Zinselmeyer, B. H.; Mackay, S. P.; Schatzlein, A. G.; Uchegbu, I. F. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm. Res., 2002, 19, 960-967.
66. de Brabander-van den Berg, E. M. M. M., E.W. Poly(propylene imine) Dendrimers: Large-Scale Synthesis via Heterogeneously Catalyzed Hydrogenation. Angew. Chem. Int. Ed. Engl., 1993, 32, 1308-1311.
67. Omidi Y.; Hollins A. J.; Drayton R. M.; Akhtar S. Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J. Drug Target., 2005, 13, 431-443.
68. Elissen-Roman, C. H., J.C.M; van Baars, M.W.P.L.; Genderen, M.H.P.; van Meijer, E.W. Amphiphilic block copolymers based on quaternized poly(propylene imine) dendrimers. Polym. Mater., 1997, 214, 145-146.
69. Pan, Y.; Ford, W. T. Dendrimers with Both Hydrophilic and Hydrophobic Chains at Every End. Macromolecules, 1999, 32, 5468-5470.
70. Pan, Y.; Ford, W. T. Amphiphilic Dendrimers with Both Octyl and Triethylenoxy Methyl Ether Chain Ends. Macromolecules, 2000, 33, 3731-3738.
71. Schatzlein, A. G.; Zinselmeyer, B. H.; Elouzi, A.; Dufes, C.; Chim, Y. T.; Roberts, C. J.; Davies, M. C.; Munro, A.; Gray, A. I.; Uchegbu, I. F. Preferential liver gene expression with polypropylenimine dendrimers. J. Control. Release, 2005, 101, 247-258.
72. Tack, F.; Bakker, A.; Maes, S.; Dekeyser, N.; Bruining, M.; Elissen-Roman, C.; Janicot, M.; Janssen, H. M.; De Waal, B. F.; Fransen, P. M.; Lou, X.; Meijer, E. W.; Arien, A.; Brewster M. E. Dendrimeric poly(propylene-imines) as effective delivery agents for DNAzymes: toxicity, in vitro transfection and in vivo delivery. J. Control. Rel., 2006, 116, 26-28.
73. Tack, F.; Bakker, A.; Maes, S.; Dekeyser, N.; Bruining, M.; Elissen-Roman, C.; Janicot, M.; Brewster, M.; Janssen, H. M.; De Waal, B. F. M.; Fransen, P. M.; Lou, X.; Meijer, E. W. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J. Drug Target., 2006, 14, 69-86.
74. Taratula, O.; Garbuzenko, O. B.; Kirkpatrick, P.; Pandya, I.; Savla, R.; Pozharov, V. P.; He H.; Minko, T. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release, 2009.
75. Shen, W. C.; Ryser, H. J. Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins. Proc. Natl. Acad. Sci. USA, 1978, 75, 1872-1876.
76. Ryser, H. J. A membrane effect of basic polymers dependent on molecular size. Nat., 1967, 215, 934-936.
77. Ryser, H. J. Uptake of protein by mammalian cells: an underdeveloped area. The penetration of foreign proteins into mammalian cells can be measured and their functions explored. Science, 1968, 159, 390-396.
78. Denkewalter, R.G; Kole, J.F; Lukasavage, W.J. US Pat. 4 410 688, 1983.
79. Yamagata, M.; Kawano, T.; hiba, K.; Mori, T.; Katayama, Y.; Niidome, T. Structural advantage of dendritic poly(L-lysine) for gene delivery into cells. Bioorg. Med. Chem., 2007, 15, 526-532.
80. Eom, K. D.; Park, S. M.; Tran, H. D.; Kim, M. S.; Yu, R. N.; Yoo, H. Dendritic alpha,epsilon-poly(L-lysine)s as delivery agents for antisense oligonucleotides. Pharm. Res., 2007, 24, 1581-1589.
81. Marano, R. J.; Wimmer, N.; Kearns, P. S.; Thomas, B. G.; Toth, I.; Brankov M.; Rakoczy, P. E. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp. Eye Res., 2004, 79, 525-535.
82. Wimmer, N.; Marano, R. J.; Kearns, P. S.; Rakoczy, E. P.; Toth, I. Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. Bioorg. Med. Chem. Lett., 2002, 12, 2635-2637.
83. Bermejo, J. F.; Ortega, P.; Chonco, L.; Eritja, R.; Samaniego, R.; Mullner, M.; de Jesus, E.; de la Mata, F. J.; Flores, J. C.; Gomez, R.; Munoz-Fernandez, A. Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry, 2007, 13, 483-495.
84. Shcharbin, D.; Pedziwiatr, E.; Chonco, L.; Bermejo-Martin, J. F.; Ortega, P.; de la Mata, F. J.; Eritja, R.; Gomez, R.; Klajnert, B.; Bryszewska, M.; Munoz-Fernandez, M. A. Analysis of interaction between dendriplexes and bovine serum albumin. Biomacromolecules, 2007, 8, 2059-2062.
85. Weber, N.; Ortega, P.; Clemente, M. I.; Shcharbin, D.; Bryszewska, M.; de la Mata, F. J.; Gomez, R.; Munoz-Fernandez, M. A. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Contro.l Release., 2008, 132, 55-64.
86. Gras, R.; Almonacid, L.; Ortega, P.; Serramia, M. J.; Gomez, R.; de la Mata, F. J.; Lopez-Fernandez, L. A.; Munoz-Fernandez, M. A. Changes in gene expression pattern of human primary macrophages induced by carbosilane dendrimer 2G-NN16. Pharm. Res., 2009, 26, 577-586.